Although the Asia-Pacific region has yet to implement a standardized process for conducting ediscovery, most Asian countries have blocking statutes or privacy laws that restrict the transfer of personal data — generally defined as any data that can identify an individual — outside their borders.
The purpose of this guide is to provide an overview of international and national anti-corruption regimes within an Asia Pacific context. It highlights how corporations should best approach anti-corruption compliance, transactional and third party due diligence and corruption investigations. It also examines related issues from anti-money laundering and whistleblowing regimes.
Many jurisdictions in the Asia-Pacific region have enacted, or are in the process of enacting, comprehensive data privacy legislation. Learn how this may impact your business.
Bringing a drug to market requires an extraordinary investment. In-house counsel at biotech and pharmaceutical companies routinely face the challenge of developing an IP strategy that maximizes an investment’s return. This is especially difficult when the market for approval of a drug is relatively small. This article provides an overview of the regulatory frameworks for orphan drugs in the United States and other developed and emerging markets.
This White Paper is the full version of the March 2013 Asian Briefings article, "Privacy Statutes in Asia-Pacific Jurisdictions." In addition to serving as a primer on privacy statutes in Asia-Pacific jurisdictions, this White Paper also examines the conflict between the US ediscovery laws and the privacy laws and regulations in the Asian-Pacific region, and attempts by the US Court to reconcile such conflicts. It also recommends best practices for navigating the minefield that exists as a result of such conflicts.
This article offers a brief analysis of data privacy laws and regulations in some key Asia-Pacific jurisdictions, including China, Japan, Australia, South Korea, New Zealand, Taiwan, Singapore, Hong Kong, and India.
This survey is a self-proclaimed 'work in progress' which will continue to be updated by the Pro Bono Institute. It covers 43 jurisdictions in Europe, Asia and the Pacific region, the Americas, Africa, and the Middle East.
Tips on how to make a business trip a bit more positive.
This article focuses on the challenges involved in the discovery phase of litigation when dealing with foreign companies. Understand what obstacles can impede the discovery process and what legal measures, if any, may be taken to avoid these complications.
In this edition, the Docket reviews what every company in in the region needs to know in order to succeed, as well as providing a toolkit for counsel on mitigating IP loss exposure in China.